Research & Innovation
UWF Professor Patents Brain-Wave Test for Early Alzheimer’s Detection
Dr. James Arruda’s 29-year research journey has yielded a non-invasive, low-cost EEG platform that may detect cognitive decline years before symptoms appear.
A University of West Florida psychology professor has cleared a major hurdle on the path to a more accessible Alzheimer’s diagnostic tool. Dr. James Arruda has received a Notice of Allowance from the U.S. Patent and Trademark Office for his Flash Visual Evoked Potential-P2 (FVEP-P2) platform—an EEG-based technology that detects mild cognitive impairment linked to Alzheimer’s dementia by measuring how quickly the brain responds to brief flashes of light.
The response speed, Arruda’s research shows, is selectively delayed in patients whose mild cognitive impairment often precedes Alzheimer’s—potentially flagging the disease years before cognitive symptoms appear.
Why It Matters
Alzheimer’s is almost always diagnosed after symptoms are well established, limiting the window for effective intervention. That window has grown more critical with the recent FDA approval of the first disease-modifying therapies for early Alzheimer’s—treatments that work best when started early.
“This Notice of Allowance brings us closer to giving clinicians a tool that is less expensive, more accessible and less invasive than the current standard for early Alzheimer’s detection.” —Dr. James Arruda
Current gold-standard diagnostics—PET imaging and cerebrospinal fluid analysis—are expensive, invasive, and not widely available. The FVEP-P2 platform uses standard EEG equipment already found in clinics, making it a realistic option for primary care practices, memory clinics, and neurology offices.
The Road to the Patent
The allowed patent is the product of nearly three decades of work:
- Arruda has studied the targeted brain response for 29 years
- Initial clinical trials at Brown University supported continued development
- In 2022, UWF entered a licensing agreement with BIOPAC Systems Inc., a California biomedical research company—the university’s third-ever licensing deal
- With the patent now allowed, Arruda and BIOPAC are moving into pre-submission with the FDA—a process that may move faster than typical because the underlying EEG hardware is already FDA-cleared
UWF’s Jerry Lin, associate vice president of Research Administration and Engagement, called the platform “a significant innovation that allows non-intrusive detection of early cognitive declines,” adding that it carries “commercialization potential that will benefit many patients in need and substantially reduce the medical costs associated with treating cognitive impairments.”
What’s Next
BIOPAC CEO Frazer Findlay said the company remains focused on moving the technology through the regulatory process and into clinical use. The next phase involves formal FDA engagement, with the goal of making the platform available to clinicians—and ultimately to patients who could benefit from earlier intervention.
For Arruda, the milestone is deeply personal. “I have been studying this particular brain response for the past 29 years,” he said. “It is gratifying to know that my work has contributed to the scientific and medical community’s understanding of information processing in general, and that it may also prove clinically useful to those with mild cognitive impairment and Alzheimer’s dementia.”
I have followed Dr. Arruda’s research for years. Here is a podcast from March 2022:
